Insider Selling: Pulse Biosciences (NASDAQ:PLSE) Insider Sells $429,000.00 in Stock

Pulse Biosciences, Inc (NASDAQ:PLSE) insider Kevin Patrick Danahy sold 20,000 shares of the firm’s stock in a transaction on Monday, February 9th. The stock was sold at an average price of $21.45, for a total value of $429,000.00. Following the completion of the sale, the insider directly owned 43,298 shares of the company’s stock, valued at $928,742.10. The trade was a 31.60% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Kevin Patrick Danahy also recently made the following trade(s):

• On Wednesday, February 11th, Kevin Patrick Danahy sold 20,000 shares of Pulse Biosciences stock. The shares were sold at an average price of $25.20, for a total transaction of $504,000.00.

Pulse Biosciences Trading Down 1.7%

Shares of NASDAQ PLSE opened at $23.01 on Friday. The firm has a fifty day simple moving average of $15.36 and a two-hundred day simple moving average of $15.77. Pulse Biosciences, Inc has a 12 month low of $12.56 and a 12 month high of $26.30. The firm has a market capitalization of $1.56 billion, a PE ratio of -20.36 and a beta of 1.77.

Wall Street Analyst Weigh In

Several analysts have weighed in on PLSE shares. Mizuho set a $30.00 price objective on Pulse Biosciences in a research report on Friday, February 6th. Weiss Ratings restated a “sell (d-)” rating on shares of Pulse Biosciences in a research note on Thursday, January 22nd. Two investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $26.00.

Institutional Investors Weigh In On Pulse Biosciences

Several hedge funds have recently made changes to their positions in the company. BNP Paribas Financial Markets lifted its position in Pulse Biosciences by 63.6% during the second quarter. BNP Paribas Financial Markets now owns 1,749 shares of the company’s stock valued at $26,000 after acquiring an additional 680 shares during the last quarter. Tower Research Capital LLC TRC increased its position in shares of Pulse Biosciences by 275.0% during the second quarter. Tower Research Capital LLC TRC now owns 2,940 shares of the company’s stock worth $44,000 after purchasing an additional 2,156 shares in the last quarter. Russell Investments Group Ltd. increased its position in shares of Pulse Biosciences by 44.0% during the third quarter. Russell Investments Group Ltd. now owns 4,487 shares of the company’s stock worth $79,000 after purchasing an additional 1,372 shares in the last quarter. KLP Kapitalforvaltning AS lifted its holdings in shares of Pulse Biosciences by 136.0% during the 3rd quarter. KLP Kapitalforvaltning AS now owns 5,900 shares of the company’s stock valued at $104,000 after purchasing an additional 3,400 shares during the last quarter. Finally, AlphaQuest LLC boosted its position in shares of Pulse Biosciences by 184.5% in the 2nd quarter. AlphaQuest LLC now owns 8,864 shares of the company’s stock worth $134,000 after purchasing an additional 5,748 shares in the last quarter. 76.95% of the stock is currently owned by hedge funds and other institutional investors.

Pulse Biosciences Company Profile

Pulse Biosciences, Inc is a clinical-stage bioelectric medicine company that develops and commercializes medical devices based on its proprietary Tissue NanoPoration (TNP) platform. The company’s core technology, NanoPulse Stimulation (NPS), delivers ultrashort, high-voltage electric pulses to targeted tissue, triggering cellular responses without the thermal damage associated with traditional energy-based devices. Pulse Biosciences focuses on applications in dermatology and aesthetic medicine, where controlled ablation of unwanted lesions is critical.

The company’s flagship product, the CellFX® System, is designed to treat a range of benign and malignant skin lesions, including seborrheic keratosis, non-melanoma skin cancers, and various epidermal and dermal lesions.